Navigation Links
Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
Date:1/22/2008

candidate is intravenous iclaprim, a potent late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In March 2007, Arpida completed patient enrolment in the second pivotal Phase III trial in complicated skin and skin structure infections. The top-line data of the second trial were reported in July 2007. The NDA-filing process is ongoing and expected to be completed by the end of February 2008.

In December 2007, Arpida announced the enrolment and dosing of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal th
'/>"/>

SOURCE Arpida Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  MiMedx Group, Inc. ... utilizing human amniotic tissue and patent-protected processes to develop ... Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental ... Parker H. "Pete" Petit, has been awarded the Lifetime ... 2015 Southeast Program. The Entrepreneur Of ...
(Date:6/29/2015)... , June 29, 2015   Veracyte, Inc ... pioneering the field of molecular cytology, today announced that ... Group,s prestigious Top Workplaces list for the second year ... winners based solely on an annual survey of Bay ... honored that the degree to which Veracyte values our ...
(Date:6/26/2015)... Kan. , June 26, 2015 /PRNewswire/ ... PETX ), a pet therapeutics company focused ... innovative biopharmaceutical products for companion animals, today ... effectiveness study of capromorelin (AT-002), the company,s ... Capromorelin is a small molecule that mimics ...
(Date:6/26/2015)... MUMBAI, India , June 26, 2015  Tata ... global IT services, consulting and business solutions organization, announced ... Worldwide Life Sciences R&D Risk-Based Monitoring by global market ... Life Science R&D Risk-Based Monitoring 2015 Vendor Assessment," (doc ... evaluated eight leading IT services vendors with significant RBM ...
Breaking Biology Technology:EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 2TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 3TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 4
... www.tedmed.com , the world,s leading multi-disciplinary conference on the future ... of the conference will take place in Washington, DC at ... April 11-13, 2012. From 2009 to 2011, San ... and technology developers. The move to the Nation,s Capital and ...
... -- Andrew Barron, Rice University,s Charles W. Duncan, Jr. ... science, is the winner of the prestigious 2011 World ... the World Technology Summit and Awards gala at the ... the application of nanotechnology to fundamental problems in energy ...
... VetNostic Laboratories® offers state-of-the-art genetic testing services for ... are able to accurately and specifically determine whether ... reliable identification of these "carriers" ensures healthy litters ... VetNostic Laboratories® is pleased to introduce two new ...
Cached Biology Technology:TEDMED Announces Move to Washington, DC; the John F. Kennedy Center for Performing Arts Will Host TEDMED 2012 Conference 2TEDMED Announces Move to Washington, DC; the John F. Kennedy Center for Performing Arts Will Host TEDMED 2012 Conference 3TEDMED Announces Move to Washington, DC; the John F. Kennedy Center for Performing Arts Will Host TEDMED 2012 Conference 4TEDMED Announces Move to Washington, DC; the John F. Kennedy Center for Performing Arts Will Host TEDMED 2012 Conference 5Rice's Barron wins World Technology Award for Materials 2VetNostic Laboratories® Announces New Testing for Dog Breeds 2VetNostic Laboratories® Announces New Testing for Dog Breeds 3
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - ... partnership centralized around the incorporation of handyem,s HPC-150 ... diagnostic laboratory, the Mo-POD™. This unprecedented model of ... International Conference at the Pennsylvania ... from June 15 th to 18 th ...
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue guidance for ... at least 340 MSEK to that it will amount to ... growth and orders received the revenue guidance for 2015 is ... will exceed 1,500 MSEK to an updated guidance that revenue ... Due to receipt of orders of touch fingerprint sensors with ...
(Date:6/15/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... market, announces that its leading payment security technology, the Wocket® ... @ NYC June 18th. Digital Experience! @ NYC ... technology to over 300 of the top media covering the ... in New York City from 6:00 ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... cells become after being exposed to a specialized electrical ... cancerous or a stage of cancer already invading other ... the electrical process and found cells that expanded the ... disease has spread beyond its point of origin. The ...
... power to constrict blood vessels and help patients manage ... more about how endothelin functions naturally and in disease ... Despite strong laboratory evidence that blocking endothelin-1 receptors would ... health problems, the drugs failed patients, says Dr. Adviye ...
... Within the last few years the number of ... increased considerably. A worthwhile effort as, after all, it concerns ... of transport checks are offered by terahertz radiation. Before this ... to be measured quantitatively, so that damage to health caused ...
Cached Biology News:Expanding cell girth indicates seriousness of breast cancer 2Better understanding of blood vessel constrictor needed to harness its power for patients 2Checking people at airports -- with terahertz radiation 2
... containing an overproducing clone of M-MLV Reverse ... the polymerization of DNA using template DNA, ... large mRNAs, >10 kb, may be synthesized. ... RNase H activity than AMV Reverse Transcriptase ...
... catalyzes the template-directed polymerization of nucleotides into ... Polymerase I possesses a 3?5 exonuclease activity ... rate during DNA replication, and also contains ... enzyme to replace nucleotides in the growing ...
Request Info...
... yeast/leuconostoc overproducer ATP: D-hexose 6- ... One unit of HK will ... in 1 min at 25C ... of G6P-DH will oxidize 1 ...
Biology Products: